ADC Therapeutics
ADCT
114 hedge funds and large institutions have $86.7M invested in ADC Therapeutics in 2026 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 42 increasing their positions, 30 reducing their positions, and 30 closing their positions.
19,100% more call options, than puts
Call options by funds: $192K | Put options by funds: $1K
40% more repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 30
2.25% less ownership
Funds ownership: 65.74% → 63.49% (-2.2%)
3% less funds holding
Funds holding: 118 → 114 (-4)
10% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 30
72% less capital invested
Capital invested by funds: $313M → $86.7M (-$226M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$19.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$4.82M |
| 3 |
BlackRock
New York
|
+$2.24M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.04M |
| 5 |
D.E. Shaw & Co
New York
|
+$1.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$21.4M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$11.5M |
| 3 |
O
OrbiMed
New York
|
-$4.94M |
| 4 |
Morgan Stanley
New York
|
-$2.22M |
| 5 |
VCM
Voleon Capital Management
Berkeley,
California
|
-$1.93M |
ADCT Hedge Fund Activity: Q2 2026 in Review
114 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2026, worth a combined $86.7M — down 72% from $313M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ADCT and 27 opened new positions — a net loss of 3 holders — while 30 trimmed existing stakes and 42 added.
The largest buyer was Nantahala Capital Management, adding an estimated $19.6M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $21.4M sold.
- 114 institutional investors held ADC Therapeutics (ADCT) as of Q2 2026, down from 118 in Q1 2026.
- Funds reported $86.7M of ADC Therapeutics stock for Q2 2026, down 72% quarter-over-quarter.
- 27 funds opened new ADC Therapeutics positions in Q2 2026 and 30 closed out, a net change of -3 holders.
- The largest ADC Therapeutics buyer in Q2 2026 was Nantahala Capital Management, an estimated $19.6M added.
- The largest ADC Therapeutics seller in Q2 2026 was Eventide Asset Management, an estimated $21.4M sold.
Based on aggregated 13F filings for Q2 2026.